Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
American Journal of Hypertension|July 5, 2020
Effect of Lower Blood Pressure Goals on Left Ventricular Structure and Function in Patients With Subclinical Hypertensive Heart DiseasePhillip D Levy, Michael J Burla, Michael J Twiner, et al.
The New England Journal of Medicine|September 1, 2025
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant HypertensionJohn M Flack, Michel Azizi, Jenifer M Brown, et al.
Hypertension (Dallas, Tex. : 1979)|January 22, 2025
Aprocitentan for Blood Pressure Reduction in Black PatientsJohn M Flack, Markus P Schlaich, Michael A Weber, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|November 1, 2016
Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost-effectiveness AnalysisMichael J Twiner, Alexander L Marinica, Kenneth Kuper, et al.
American Journal of Hypertension|August 25, 2022
Does Vitamin D Provide Added Benefit to Antihypertensive Therapy in Reducing Left Ventricular Hypertrophy Determined by Cardiac Magnetic Resonance?Phillip D Levy, Michael J Twiner, Aaron M Brody, et al.
Ethnicity & Disease|November 25, 2003
The Metabolic Syndrome in African Americans: a reviewW Dallas Hall, Luther T Clark, Nanette K Wenger, et al.
Lancet (London, England)|March 7, 2026
Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trialMichel Azizi, Jenifer M Brown, Jamie P Dwyer, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|August 24, 2025
Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24John M Flack, Michel Azizi, Jenifer M Brown, et al.
Disease Management : DM|February 10, 2006
The metabolic syndrome: recognition and managementW Dallas Hall, Laurence O Watkins, Jackson T Wright, et al.
Kidney Medicine|December 4, 2023
Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD TrialsJohn M Flack, Rajiv Agarwal, Stefan D Anker, et al.
Pageof 13